3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
3
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
68
Gastrointestinal
9
Thoracic
7
Breast
7
Head & Neck
6
Gynecologic
6
Dermatologic
5
Sarcoma
3
Endocrine
2
Other solid neoplasm
1
NET
1
Lymphoid
1
CNS
1
Conditions
Neuroendocrine Tumors
70
Carcinoma, Neuroendocrine
7
Gastro-enteropancreatic neuroendocrine tumor
6
Carcinoid Tumor
6
Neoplasm Metastasis
5
Paraganglioma
3
Pancreatic Neoplasms
3
Carcinoma, Hepatocellular
3
Adenoma, Islet Cell
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Neoplasms
2
Lung Neoplasms
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Teratoma
1
Small Intestinal Neuroendocrine Tumor
1
Small Cell Lung Carcinoma
1
Rectal Neuroendocrine Tumor
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Parkinson Disease
1
Pancreatic Neuroendocrine Tumors in MEN1
1
Osteomalacia
1
Neuroendocrine Tumors With Metastasis
1
Neuroendocrine Tumors Metastatic to the Liver
1
Neuroendocrine Tumor Grade 3
1
Neuroblastoma
1
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Transitional Cell
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled